Publications, Pharmaceutical

Improving Intranasal Sprays for Respiratory Viral Infections

Intranasal sprays have considerable potential for the treatment of viral infections such as the SARS-CoV-2 virus which enter via the upper airway.

This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.

Download Publication
28 Jan 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

1 Jul 2019

Aptar Pharma discusses challenges and benefits of drug repurposing

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
3 Jun 2019

Microbial integrity testing for preservative-free drug formulations

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
1 Apr 2019

Interview with Guillaume Brouet on Aptar Pharma Services

Publications, Pharmaceutical, Innovation & Insights

Read More
18 Sep 2018

Aptar Pharma provides guidance on FDA regulatory framework for OINDPs

Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights

Read More
1 22 23 24 25
Back To Top